Other News To Note
NeurogesX Inc., of San Mateo, Calif., said the FDA's Anesthetic and Analgesic Drug Products Advisory Committee did not recommend approval of Qutenza (capsaicin 8 percent patch) for management of neuropathic pain related to HIV-associated peripheral neuropathy.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.